[A25-116] Trastuzumab deruxtecan (breast cancer) – Addendum to Project A25-54
Last updated 16.10.2025
Project no.:
A25-116
Commission:
Commission awarded on 10.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment
Unchanged after addendum: Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-116
| Project no. | Title | Status |
|---|---|---|
| A25-54 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision